The funding validates the emerging in‑vivo gene‑editing CAR‑T model, which could dramatically lower production costs and broaden access to cellular therapies across oncology and autoimmunity. Successful execution would position Azalea as a pioneer in next‑generation precision medicines, reshaping the competitive landscape of cell‑based therapeutics.
Comments
Want to join the conversation?
Loading comments...